Nippon Shinyaku Co. Ltd. (TYO:4516) has completed Phase 2 clinical trials in the U.S. for NS-065 as of this February…....
Please subscribe to read the full story.
Japan's leading chemical industry newspaper
Footer
© 2016–2022 The Chemical Daily Co. Ltd., Bonuterra Inc. All Rights Reserved.
